RWE 101 – How RWE is Being Used to Support the Treatment of Cancer
Real-world evidence (RWE) enhances cancer treatment through providing more comprehensive and personalized patient data. Here are summarized examples:
[1] Targeted Therapies for Lung Cancer: RWE aids in identifying actionable mutations in non-small-cell lung carcinoma (NSCLC), facilitating targeted treatments.
[2] Immuno-Oncology Treatments: Through studying melanoma patient responses to immune checkpoint inhibitors, RWE informs long-term safety, efficacy (effectiveness), and optimal usage.
[3] Treatment Adherence and Persistence: RWE helps determine factors affecting adherence to oral chemotherapies, enabling effective patient management.
[4] Clinical Trial Design: Real-world data can ensure clinical trial populations better reflect the real-world population’s diversity, increasing the trials’ relevance.
[5] Post-Market Surveillance: RWE allows monitoring of approved cancer drugs’ safety and effectiveness, identifying previously unknown adverse effects and comparing different treatments.
[6] Comparative Effectiveness Research: RWE can evaluate the benefits and harms of different treatments, such as drug classes or treatment methods, enhancing decision-making.
[7] Pediatric Oncology: RWE offers valuable insights into pediatric cancer treatment patterns and outcomes, critical given the ethical concerns with trials in pediatric populations.
[8] Health Economics and Outcomes Research: RWE assesses the cost-effectiveness of cancer treatments, informing coverage and reimbursement decisions.
[9] Precision Medicine: Real-world genomic data, combined with clinical outcomes, helps create more personalized treatment strategies, like using PARP inhibitors for BRCA-mutated ovarian cancer.
[10] Population Health Management: RWE can expose disparities in cancer care, prompting efforts to address these gaps.
In summary, RWE significantly contributes to cancer treatment. It complements clinical trials, supports personalized care, highlights patient voice, and improves overall cancer care quality. Despite data standardization and quality challenges, RWE’s potential to enhance cancer treatment remains vast.
Share this story...
Real World Evidence (RWE) 101 – Study Designs
RWE 101 - Study Designs Real-world evidence (RWE) studies are becoming increasingly important in healthcare decision-making. There are various study designs used to generate RWE, each with their unique [...]
Real World Evidence (RWE) 101 – Protocol Considerations
RWE 101 - Protocol Considerations Real-world evidence (RWE) study protocols and clinical trial protocols both outline the design and conduct of a study. However, they are distinctly different in [...]
Real World Evidence (RWE) 101 – PASS Approval Requirements
RWE 101 - PASS Approval Requirements Post-authorisation safety studies (PASS) are studies conducted after a medicine has been authorized (licensed) with the goal of acquiring more data about the [...]
Real World Evidence (RWE) 101 – Categories of PASS
RWE 101 - Categories of PASS Real-world evidence (RWE) is the clinical evidence about the usage and potential benefits or risks of a product derived from the analysis of [...]
Real World Evidence (RWE) 101 – Safety Monitoring
RWE 101 - Safety Monitoring Real World Evidence (RWE) complements clinical trials and provides additional insights that are difficult to achieve in controlled environments. Here's why:[1] Sample Size and [...]
Real World Evidence (RWE) 101 – How RWE is Being Used to Support the Treatment of Cancer
RWE 101 - How RWE is Being Used to Support the Treatment of Cancer Real-world evidence (RWE) enhances cancer treatment through providing more comprehensive and personalized patient data. Here [...]
